Login / Signup

Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis.

Matthew SayerGavin B ChapmanMatthew ThomasNeeraj Dhaun
Published in: Current rheumatology reports (2023)
The incidence of cardiovascular disease in AAV exceeds that expected by traditional risk factors alone, suggesting a contribution from disease-specific factors. Similarly, it is unclear how different immunosuppressive therapies contribute to and modify cardiovascular risk, and there is a paucity of data examining the efficacy of traditional cardioprotective medications in AAV. There is a lack of evidence-based cardiovascular risk assessment tools and cardioprotective therapies in patients with AAV which should be addressed to improve long-term outcomes.
Keyphrases